JoVE
JoVE
Faculty Resource Center
Research
Behavior
Biochemistry
Biology
Bioengineering
Cancer Research
Chemistry
Developmental Biology
Engineering
Environment
Genetics
Immunology and Infection
Medicine
Neuroscience
JoVE Journal
JoVE Encyclopedia of Experiments
JoVE Chrome Extension
Education
Biology
Chemistry
Clinical
Engineering
Environmental Sciences
Pharmacology
Physics
Psychology
Statistics
JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Quiz
JoVE Business
Videos Mapped to your Course
Authors
Librarians
High Schools
About
Sign-In
Sign In
Contact Us
Research
JoVE Journal
JoVE Encyclopedia of Experiments
Education
JoVE Core
JoVE Science Education
JoVE Lab Manual
High Schools
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
Close
Research
Behavior
Biochemistry
Bioengineering
Biology
Cancer Research
Chemistry
Developmental Biology
Engineering
Environment
Genetics
Immunology and Infection
Medicine
Neuroscience
Products
JoVE Journal
JoVE Encyclopedia of Experiments
Education
Biology
Chemistry
Clinical
Engineering
Environmental Sciences
Pharmacology
Physics
Psychology
Statistics
Products
JoVE Core
JoVE Science Education
JoVE Lab Manual
JoVE Quiz
JoVE Business
Videos Mapped to Your Course
Teacher Resources
Get in Touch
Instant Trial
Log In
EN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
Journal
/
Cancer Research
/
EGFR変異型NSCLC患者由来オルガノイドにおける標的療法に対する感受性のプロファイリング
JoVE Journal
Cancer Research
This content is Free Access.
JoVE Journal
Cancer Research
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Please note that all translations are automatically generated.
Click here for the English version.
EGFR変異型NSCLC患者由来オルガノイドにおける標的療法に対する感受性のプロファイリング
DOI:
10.3791/63039-v
•
08:52 min
•
November 22, 2021
•
Dora Barbosa Rabago
2,3
,
Collin M. Blakely
2
,
Franziska Haderk
2,3
,
Trever G. Bivona
2,3
1
Department of Medicine
,
University of California, San Francisco
,
2
Helen Diller Family Comprehensive Cancer Center
,
University of California, San Francisco
,
3
Department of Cellular and Molecular Pharmacology
,
University of California, San Francisco
Chapters
00:04
Introduction
01:05
Generating Single-Cell Suspension
02:38
Cell Seeding
04:39
Drug Treatment
05:37
Readout by Luminescence-Based Survival Assay
06:52
Results: The Analysis of Treatment Response of EGFR-Mutant NSCLC Organoid Model to Osimertinib
08:18
Conclusion
Summary
Automatic Translation
English (Original)
العربية (Arabic)
中文 (Chinese)
Nederlands (Dutch)
français (French)
Deutsch (German)
עברית (Hebrew)
italiano (Italian)
日本語 (Japanese)
한국어 (Korean)
português (Portuguese)
русский (Russian)
español (Spanish)
Türkçe (Turkish)
Automatic Translation
このプロトコールは、NSCLC患者由来オルガノイドモデルにおける標的シグナル伝達阻害剤に対する薬物感受性の標準化された評価を記載している。
Tags
Organoids
EGFR-mutant NSCLC
Targeted Therapies
Matrigel
Cell Culture
Dissociation
Trypsinization
Centrifugation
Cell Counting
Cell Suspension
96-well Plate
Article
Embed
ADD TO PLAYLIST
Usage Statistics
Related Videos
患者由来の軟部肉腫の主な文化の確立
GFP レンチ ウイルス導入オルガノイド培養患者由来大腸腫瘍によって生成される微小の高感度検出
構造DNA改変解析と患者由来異種移植片を用いたがんの標的治療の試験
患者由来腫瘍オルガノイドを用いたイン
ビトロ
アッセイのハイスループット
患者由来の腫瘍サンプルから3次元スフェロイドを樹立し、薬物に対する感受性を評価
高悪性度漿液性卵巣癌患者由来オルガノイドの作製と培養
免疫蛍光アッセイ
による
患者由来卵巣がんオルガノイド中のDNA損傷修復タンパク質の可視化(英語)
患者由来乳房オルガノイドの確立と培養
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Cultivating Ex Vivo Patient-Derived Glioma Organoids Using a Tissue Chopper
Read Article